scholarly journals Intralesional Bleomycin for Treatment of a Recalcitrant Wart in an Immunocompromised Patient: A Safe, Effective, and Underutilized Therapy

2021 ◽  
Author(s):  
Tracy Ngo ◽  
Hannah Hwang ◽  
Bijal Amin ◽  
Steven Cohen
Keyword(s):  
Patient Satisfaction ◽  
Safety Profile ◽  
Immunocompromised Patient ◽  
Treatment Modalities ◽  
High Patient Satisfaction ◽  
Clinical Exposure ◽  
Acceptable Safety Profile

Injectable bleomycin is infrequently used for recalcitrant warts despite its efficacy, acceptable safety profile, and high patient satisfaction compared to other treatment modalities. We present an immunocompromised patient with a large recalcitrant wart successfully treated with intralesional bleomycin to provide greater clinical exposure, training, and practice with intralesional bleomycin.

Update Treatment for Prolactinoma

2018 ◽  
Vol 3 (06) ◽  
Author(s):  
Chávez Hernández María Margarita ◽  
Jiménez Báez María Valeria ◽  
Armijo Medina María Fernanda ◽  
Domínguez Leyva Jorge Miguel ◽  
Góngora Valencia Karen Alejandra ◽  
...  
Keyword(s):  
Dopamine Agonist ◽  
Safety Profile ◽  
Pituitary Tumor ◽  
Common Type ◽  
Treatment Modalities ◽  
First Line ◽  
Agonist Therapy ◽  
Dopamine Agonist Therapy ◽  
Gonadal Dysfunction

Prolactinomas are the most common type of functional pituitary tumor. The present manuscript is an update on the treatment modalities for prolactinomas. Effective hyperprolactinemia treatment is of great importance, due to its potential deleterious effects including infertility, gonadal dysfunction and osteoporosis. Dopamine agonist therapy is the first line of treatment for prolactinomas; recurrence of disease after cessation of the drug may occur in patients. Its safety profile remains high, allowing its use during pregnancy.

scholarly journals The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma

2021 ◽  
Vol 12 ◽  
pp. 204062072110196
Author(s):  
Albert Oriol ◽  
Laura Abril ◽  
Anna Torrent ◽  
Gladys Ibarra ◽  
Josep-Maria Ribera
Keyword(s):  
Multiple Myeloma ◽  
High Risk ◽  
Safety Profile ◽  
Proteasome Inhibitors ◽  
Clinical Development ◽  
Phase Iii ◽  
Acceptable Safety Profile ◽  
Refractory Multiple Myeloma ◽  
High Risk Patients ◽  
Risk Patients

The development of several treatment options over the last 2 decades has led to a notable improvement in the survival of patients with multiple myeloma. Despite these advances, the disease remains incurable for most patients. Moreover, standard combinations of alkylating agents, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies targeting CD38 and corticoids are exhausted relatively fast in a proportion of high-risk patients. Such high-risk patients account for over 20% of cases and currently represent a major unmet medical need. The challenge of drug resistance requires the development of highly active new agents with a radically different mechanism of action. Several immunotherapeutic modalities, including antibody–drug conjugates and T-cell engagers, appear to be promising choices for patients who develop resistance to standard combinations. Chimeric antigen-receptor-modified T cells (CAR-Ts) targeting B-cell maturation antigen have demonstrated encouraging efficacy and an acceptable safety profile compared with alternative options. Multiple CAR-Ts are in early stages of clinical development, but the first phase III trials with CAR-Ts are ongoing for two of them. After the recent publication of the results of a phase II trial confirming a notable efficacy and acceptable safety profile, idecabtagene vicleucel is the first CAR-T to gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy. Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma.

scholarly journals A Unique Case of Replantation of Previously Replanted Fingers

2021 ◽  
Author(s):  
Ravindra Bharathi ◽  
Praveen Bhardwaj ◽  
Vigneswaran Varadharajan ◽  
Hari Venkatramani ◽  
S Raja Sabapathy
Keyword(s):  
Patient Satisfaction ◽  
Literature Search ◽  
Standard Of Care ◽  
Unique Case ◽  
High Patient Satisfaction ◽  
Finger Amputation ◽  
Accepted Standard ◽  
Technical Challenges

AbstractReplantation of digital amputations is now the accepted standard of care. However, rarely will a replantation surgeon be presented with amputated fingers which have been previously replanted. In our literature search, we could find only one publication where a replanted thumb suffered amputation and was successfully replanted again. We report the technical challenges and the outcome of replanting two fingers which suffered amputation 40 months after the initial replantation and were successfully replanted again. Replantation was critical since the amputated fingers were the only two complete fingers in that hand which had initially suffered a four-finger amputation. The second-time replantation of previously replanted fingers is reported to allay the concern of the reconstructive surgeon when faced with this unique situation of “repeat amputation of the replanted finger.” Second-time replantation is feasible and is associated with high-patient satisfaction. Replantation must be attempted especially in the event of multiple digit amputations.

Therapy of 1,025 Severely Ill Patients with Complicated Infections in a German Multicenter Study: Safety Profile and Efficacy of Tigecycline in Different Treatment Modalities

Chemotherapy ◽  
2012 ◽  
Vol 58 (4) ◽  
pp. 282-294 ◽  
Author(s):  
Klaus-Friedrich Bodmann ◽  
Wolfgang R. Heizmann ◽  
Christof von Eiff ◽  
Christian Petrik ◽  
Peter-Andreas Löschmann ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Safety Profile ◽  
Treatment Modalities

scholarly journals Increased ROM and high patient satisfaction after open arthrolysis: a follow-up-study of 43 patients with posttraumatic stiff elbows

2016 ◽  
Vol 17 (1) ◽  
Author(s):  
Petter Morten Pettersen ◽  
Joakim Eriksson ◽  
Hallgeir Bratberg ◽  
Lars Eldar Myrseth ◽  
Lise Grete Bjørnstad ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
High Patient Satisfaction ◽  
Open Arthrolysis ◽  
Follow Up Study

The use of propofol sedation for transrectal ultrasonography-guided prostate biopsy is associated with high patient satisfaction and acceptability

2007 ◽  
Vol 63 (1) ◽  
pp. 94-95 ◽  
Author(s):  
Ninaad S. Awsare ◽  
James A. Green ◽  
Beverley Aldwinckle ◽  
Damian C. Hanbury ◽  
Greg B. Boustead ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Prostate Biopsy ◽  
Transrectal Ultrasonography ◽  
High Patient Satisfaction ◽  
Propofol Sedation

Fractional carbon dioxide laser, platelet –rich plasma and narrow band ultraviolet B in the treatment of Vitiligo (A prospective randomized comparative trial)

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Mohamed Abdullah Eshafi ◽  
Nehal Mohamed Zuelfakkar ◽  
Ahmed Abd Elfattah Afify
Keyword(s):  
Patient Satisfaction ◽  
Co2 Laser ◽  
Platelet Rich Plasma ◽  
Ultraviolet B ◽  
Treatment Modalities ◽  
Computer Assisted ◽  
Triple Combination ◽  
Patient Satisfaction Score ◽  
Triple Combination Therapy ◽  
Melanin Pigmentation

Abstract Vitiligo is a disease that causes the loss of skin color in patches due to loss of melanin pigmentation of specific areas of the skin. Although several hypotheses have been proposed, the leading theory is still the auto-immune etiology linked to specific genetic mutations. Vitiligo can also be associated with several autoimmune diseases. There is no curative treatment for vitiligo but, several treatment modalities are considered. Topical therapies like steroids and Calcineurin inhibitors are of popular use in clinical settings also, steroids can be administered systemically in vitiligo patients. Physical therapies as fractionated CO2 (Fr: CO2) laser and Narrowband-UV (NBUV) phototherapy represent a gold standard in treatment in clinical practice. Moreover, intralesional therapies are emerging, one of which is autologous platelet-rich plasma injection. Aim of the study This study aimed to evaluate and compare the efficacy and safety of Fr: CO2 laser, PRP, combined Fr: CO2 laser and PRP, combined Fr: CO2 laser and NB-UVB, combined Fr: CO2 laser, PRP and NB-UVB in the treatment of vitiligo as well as reporting the side effects. Patients and methods This study included 20 vitiligo patients with at least 6 patches of stable vitiligo (120 patches), the patches were divided into six groups according to the treatment modality. Assessment of treatment response was done through patient satisfaction score and Vitiligo analysis by computer-assisted grid (VACAG). Results Regarding surface area reduction in included patients, fractional CO2 laser achieved the best results followed by triple combination therapy (CO2 with PRP and NB-UVB), the least response was with CO2 with PRP treatment. Patient satisfaction in the current study had a different outcome, PRP treated patients exhibited the highest satisfaction scores while triple combination treated group showed the least satisfaction scores.

scholarly journals Residents Achieve a High Patient Satisfaction in Pre-Anesthetic Patient Assessment. An Observational Study

2014 ◽  
Vol 04 (11) ◽  
pp. 263-275
Author(s):  
Ulrike Reuter ◽  
Babette Jurack ◽  
Nils Engelmann ◽  
Thilo Busch ◽  
Joerg Schnoor
Keyword(s):  
Patient Satisfaction ◽  
Observational Study ◽  
Patient Assessment ◽  
High Patient Satisfaction
Sign in / Sign up

Export Citation Format

Share Document